Skip to main
PROK

ProKidney (PROK) Stock Forecast & Price Target

ProKidney (PROK) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 80%
Buy 0%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

ProKidney is seeking approval for their autologous cell therapy, rilparencel, for the treatment of moderate to severe CKD and T2D, and the company's pipeline consists of the development program for severe diabetic kidney disease. With promising results from Phase 2 and agreement with the FDA to use eGFR slope as a surrogate endpoint for their BLA submission, ProKidney is well-positioned for upcoming milestones and potential market launch. While competition exists, ProKidney's therapy is currently the only one in Phase 3 trials and has the potential to delay the need for dialysis, making it a strong candidate in the market.

Bears say

ProKidney is a clinical-stage biotechnology company with a negative outlook due to the risks associated with their product, rilparencel. While the therapy has shown promise in trials, there is still uncertainty around its efficacy and regulatory approval. Additionally, the company's dependence on this one product and the limited market for this niche indication could pose challenges to its long-term success.

ProKidney (PROK) has been analyzed by 5 analysts, with a consensus rating of Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProKidney and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProKidney (PROK) Forecast

Analysts have given ProKidney (PROK) a Buy based on their latest research and market trends.

According to 5 analysts, ProKidney (PROK) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProKidney (PROK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.